BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 17243522)

  • 1. Treatment and renal outcome of lupus nephritis: single center experience.
    Go KW; Teo SM
    Med J Malaysia; 2006 Oct; 61(4):447-50. PubMed ID: 17243522
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The prognosis of biopsy-proven lupus nephritis in chinese patients: long term follow-up of 86 cases.
    Shen K; Yu Y; Tang Z; Liu Z; Li L
    Chin Med J (Engl); 1997 Jul; 110(7):502-7. PubMed ID: 9594205
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical, biochemical and pathological predictors of poor response to intravenous cyclophosphamide in patients with proliferative lupus nephritis.
    Conlon PJ; Fischer CA; Levesque MC; Smith SR; St Clair EW; Allen NB; Fleming JA; Howell DN
    Clin Nephrol; 1996 Sep; 46(3):170-5. PubMed ID: 8879851
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictors and outcome of renal flares after successful cyclophosphamide treatment for diffuse proliferative lupus glomerulonephritis.
    Mok CC; Ying KY; Tang S; Leung CY; Lee KW; Ng WL; Wong RW; Lau CS
    Arthritis Rheum; 2004 Aug; 50(8):2559-68. PubMed ID: 15334470
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Systemic lupus erythematosus in Thai children: clinicopathologic findings and outcome in 82 patients.
    Pattaragarn A; Sumboonnanonda A; Parichatikanond P; Supavekin S; Suntornpoch V; Vongjirad A
    J Med Assoc Thai; 2005 Nov; 88 Suppl 8():S232-41. PubMed ID: 16856445
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term outcome of diffuse proliferative lupus glomerulonephritis treated with cyclophosphamide.
    Mok CC; Ying KY; Ng WL; Lee KW; To CH; Lau CS; Wong RW; Au TC
    Am J Med; 2006 Apr; 119(4):355.e25-33. PubMed ID: 16564783
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment with cyclophosphamide delays the progression of chronic lesions more effectively than does treatment with azathioprine plus methylprednisolone in patients with proliferative lupus nephritis.
    Grootscholten C; Bajema IM; Florquin S; Steenbergen EJ; Peutz-Kootstra CJ; Goldschmeding R; Bijl M; Hagen EC; Van Houwelingen HC; Derksen RH; Berden JH;
    Arthritis Rheum; 2007 Mar; 56(3):924-37. PubMed ID: 17328070
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Early response to immunosuppressive therapy predicts good renal outcome in lupus nephritis: lessons from long-term followup of patients in the Euro-Lupus Nephritis Trial.
    Houssiau FA; Vasconcelos C; D'Cruz D; Sebastiani GD; de Ramon Garrido E; Danieli MG; Abramovicz D; Blockmans D; Mathieu A; Direskeneli H; Galeazzi M; Gül A; Levy Y; Petera P; Popovic R; Petrovic R; Sinico RA; Cattaneo R; Font J; Depresseux G; Cosyns JP; Cervera R
    Arthritis Rheum; 2004 Dec; 50(12):3934-40. PubMed ID: 15593207
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Longterm followup of childhood lupus nephritis.
    Hagelberg S; Lee Y; Bargman J; Mah G; Schneider R; Laskin C; Eddy A; Gladman D; Urowitz M; Hebert D; Silverman E
    J Rheumatol; 2002 Dec; 29(12):2635-42. PubMed ID: 12465165
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Determinants of renal functional outcome in lupus nephritis: a single centre retrospective study.
    Chrysochou C; Randhawa H; Reeve R; Waldek S; Wood GN; O'Donoghue DJ; Kalra PA
    QJM; 2008 Apr; 101(4):313-6. PubMed ID: 18270227
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide.
    Houssiau FA; Vasconcelos C; D'Cruz D; Sebastiani GD; Garrido Ed Ede R; Danieli MG; Abramovicz D; Blockmans D; Mathieu A; Direskeneli H; Galeazzi M; Gül A; Levy Y; Petera P; Popovic R; Petrovic R; Sinico RA; Cattaneo R; Font J; Depresseux G; Cosyns JP; Cervera R
    Arthritis Rheum; 2002 Aug; 46(8):2121-31. PubMed ID: 12209517
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical outcomes of patients with biopsy-proven lupus nephritis in NUH.
    Gan HC; Hyoon K; Fong KY
    Singapore Med J; 2002 Dec; 43(12):614-6. PubMed ID: 12693764
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The difference between lupus nephritis class IV-G and IV-S in Koreans: focus on the response to cyclophosphamide induction treatment.
    Kim YG; Kim HW; Cho YM; Oh JS; Nah SS; Lee CK; Yoo B
    Rheumatology (Oxford); 2008 Mar; 47(3):311-4. PubMed ID: 18204087
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intravenous cyclophosphamide for lupus nephritis in Thai children.
    Vachvanichsanong P; Dissaneewate P; Winn T
    Scand J Rheumatol; 2004; 33(5):339-42. PubMed ID: 15513684
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outcome of 85 lupus nephritis patients treated with intravenous cyclophosphamide: a single centre 10 year experience.
    Chan AY; Hooi LS
    Med J Malaysia; 2000 Mar; 55(1):14-20. PubMed ID: 11072485
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The efficacy of intravenous pulse cyclophosphamide in the treatment of severe lupus nephritis in children.
    Tangnararatchakit K; Tapaneya-Olarn C; Tapaneya-Olarn W
    J Med Assoc Thai; 1999 Nov; 82 Suppl 1():S104-10. PubMed ID: 10730528
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Histopathologic and clinical outcome of rituximab treatment in patients with cyclophosphamide-resistant proliferative lupus nephritis.
    Gunnarsson I; Sundelin B; Jónsdóttir T; Jacobson SH; Henriksson EW; van Vollenhoven RF
    Arthritis Rheum; 2007 Apr; 56(4):1263-72. PubMed ID: 17393458
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Intermittent intravenous administration of cyclophosphamide in patients with lupus nephritis].
    Morović-Vergles J; Galesić K; Dancuo I; Vergles D
    Acta Med Croatica; 2004; 58(1):13-7. PubMed ID: 15125388
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Renal outcome in patients with lupus nephritis using a steroid-free regimen of monthly intravenous cyclophosphamide: a prospective observational study.
    Fischer-Betz R; Chehab G; Sander O; Vordenbäumen S; Voiculescu A; Brinks R; Schneider M
    J Rheumatol; 2012 Nov; 39(11):2111-7. PubMed ID: 22984276
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatocyte growth factor and transforming growth factor beta1 ratio at baseline can predict early response to cyclophosphamide in systemic lupus erythematosus nephritis.
    Capuano A; Costanzi S; Peluso G; Zannoni G; Vellone VG; Gremese E; Zoli A; Scott C; Beltrami CA; Romano G; Ferraccioli G
    Arthritis Rheum; 2006 Nov; 54(11):3633-9. PubMed ID: 17075808
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.